Delamanid is partly metabolised by CYP 3A4 but, is not an inhibitor or an inducer of CYP enzymes.

Delamanid is a nitro-dihydro-imidazooxazole antimycobacterial drug.

Delamanid is indicated for treatment of multidrug-resistant pulmonary tuberculosis and is used in combination with other antitubercular agents. It is administered orally. Delamanid has a half-life of about 30-38 hours (EMA, DrugBank).

Delamanid is rapidly metabolised to its main metabolite, DM-6705 in plasma by albumin. CYP 3A4 is only to a minor extent involved in formation of DM-6705 and its further transformation. In an in vitro study it was shown that delamanid had no potential for induction of CYP1A2, CYP2B6, CYP2C9, and CYP3A4, and no potential for inhibition CYP1A2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. The metabolites showed weak inhibitory effect on some CYP enzymes, but only at concentrations that were well above those observed in human plasma (Shimokawa 2014) Delamanid shows low potential for CYP related drug-drug interactions, bot as perpetrator and as victim drug. Still, co administration with strong CYP 3A4 inducers are warned against (Lexi-Interact, Mallikaarjun 2016)